Bender Robert & Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $212K | Buy |
+23,710
| New | +$212K | 0.05% | 44 |
|
|
2025
Q1 | – | Sell |
-23,710
| Closed | -$178K | – | 42 |
|
|
2024
Q4 | $178K | Buy |
+23,710
| New | +$178K | 0.04% | 45 |
|
|
2024
Q1 | – | Sell |
-56,600
| Closed | -$339K | – | 44 |
|
|
2023
Q4 | $339K | Hold |
56,600
| – | – | 0.09% | 40 |
|
|
2023
Q3 | $401K | Sell |
56,600
-12,000
| -17% | -$85K | 0.12% | 39 |
|
|
2023
Q2 | $483K | Hold |
68,600
| – | – | 0.13% | 39 |
|
|
2023
Q1 | $572K | Buy |
+68,600
| New | +$572K | 0.18% | 41 |
|
|
2022
Q4 | – | Sell |
-68,600
| Closed | -$864K | – | 49 |
|
|
2022
Q3 | $864K | Hold |
68,600
| – | – | 0.33% | 34 |
|
|
2022
Q2 | $726K | Buy |
+68,600
| New | +$726K | 0.28% | 36 |
|